Nektar Therapeutics (NASDAQ: NKTR) and aTyr Pharma (NASDAQ:LIFE) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
This table compares Nektar Therapeutics and aTyr Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings for Nektar Therapeutics and aTyr Pharma, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Nektar Therapeutics presently has a consensus price target of $36.64, suggesting a potential downside of 46.15%. aTyr Pharma has a consensus price target of $5.00, suggesting a potential upside of 29.87%. Given aTyr Pharma’s higher possible upside, analysts plainly believe aTyr Pharma is more favorable than Nektar Therapeutics.
Institutional and Insider Ownership
96.0% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 58.3% of aTyr Pharma shares are held by institutional investors. 5.4% of Nektar Therapeutics shares are held by insiders. Comparatively, 33.3% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Nektar Therapeutics and aTyr Pharma’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Nektar Therapeutics||$165.44 million||64.75||-$153.52 million||($0.71)||-95.82|
|aTyr Pharma||N/A||N/A||-$57.85 million||($2.04)||-1.89|
aTyr Pharma has lower revenue, but higher earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.
About aTyr Pharma
aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.